Topic:

R&D

Latest Headlines

Latest Headlines

ProNAi, with delivery tech licensed from Marina, snags $59.5M for cancer trials

Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech.

WuXi poaches an AstraZeneca exec to amp up Chinese R&D

Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.

Zafgen tees up an $86M IPO for eye-catching obesity drug

Zafgen has been turning heads with some jaw-dropping results from its mid-stage studies for a promising new obesity drug. And now the biotech hopes to parlay its eye-catching, if risky, technology into an $86 million IPO.

Pfizer, AstraZeneca back a new strategy for cancer drug R&D

A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.

Sanofi and Pitt join up to test wannabe dengue blockbuster

Sanofi's dengue fever candidate is on the verge of regulatory applications after 20 years in the lab and more than $1.4 billion spent on R&D. Now the pharma giant has forged a new collaboration to help assess the jab's postintroduction effectiveness.

ForSight Vision5 ropes in $15M in Series C financing to develop its intraocular therapy

ForSight Vision5 raised $15 million in a Series C financing and completed enrollment of a Phase II clinical study to support the development of its noninvasive ocular implant therapy for eye diseases.  

Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate'

The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.

Study: Inhalable encapsulated antibiotic from Aradigm kills 99% of infections

A team of scientists from Oregon State University and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for infections associated with the lungs.

InVentiv signs up to get IntelliCell's regenerative drug into the clinic

CRO inVentiv Health is teaming up with IntelliCell BioSciences to get the biotech's regenerative medicine candidate through the IND stage, pitching in to develop a novel treatment for osteoarthritis of the knee.

Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy

Parisian biotech AAVLife has come out of stealth with a Versant Ventures-led $12 million A round, looking to advance a gene-deleting therapy that promises to treat the rare and deadly Friedreich's ataxia.